S291: PHASE I/II STUDY OF RILZABRUTINIB, AN ORAL BRUTON TYROSINE KINASE INHIBITOR, IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA: LONG-TERM FOLLOW-UP

• D. J. Kuter,
• M. Efraim,
• Z. Kaplan,
• J. Mayer,
• P. Choi,
• A. G. Jansen,
• V. McDonald,
• R. Baker,
• R. Bird,
• M. Garg,
• J. Gumulec,
• M. Kostal,
• T. Gernsheimer,
• W. Ghanima,
• M. Yao,
• A. Daak,
• N. Cooper

Affiliations

D. J. Kuter

1 Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, United States of America

M. Efraim

2 Multiprofile Hospital for Active Treatment Sveta Marina EAD, Varna, Bulgaria

Z. Kaplan

3 Monash Medical Centre, Clayton, Australia

J. Mayer

4 Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital, Brno, Czechia

P. Choi

5 The Canberra Hospital, Garran, Australia

A. G. Jansen

6 Erasmus MC, University Medical Center, Rotterdam, Netherlands

V. McDonald

7 Barts Health NHS Trust, The Royal London Hospital, London, United Kingdom

R. Baker

8 Perth Blood Institute, Murdoch University, Perth

R. Bird

9 Princess Alexandra Hospital, Woolloongabba, Australia

M. Garg

10 Leicester Royal Infirmary, Leicester, United Kingdom

J. Gumulec

11 Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava

M. Kostal

12 Fourth Department of Internal Medicine and Hematology, Faculty of Medicine, University Hospital of Hradec Kralove, Hradec Kralove, Czechia

T. Gernsheimer

13 University of Washington Medical Center, Seattle, United States of America

W. Ghanima

14 Østfold Hospital Foundation, Gralum, Norway

M. Yao

15 Biostatistics, Sanofi US Services Inc., Bridgewater

A. Daak

16 Sanofi Genzyme, Cambridge, United States of America

N. Cooper

17 Department of Medicine, Hammersmith Hospital, London, United Kingdom